title: Human single-nucleotide polymorphisms alter p53 sequence-specific binding at gene regulatory elements.
abstract: p53 coordinates the expression of an intricate network of genes in response to stress signals. Sequence-specific DNA binding is essential for p53-mediated tumor suppression. We evaluated the impact of single-nucleotide polymorphisms (SNPs) in p53 response elements (p53RE) on DNA binding and gene expression in response to DNA damage. Using a bioinformatics approach based on incorporating p53 binding strength into a position weight matrix, we selected 32 SNPs in putative and validated p53REs. The microsphere assay for protein-DNA binding (MAPD) and allele-specific expression analysis was employed to assess the impact of SNPs on p53-DNA binding and gene expression, respectively. Comparing activated p53 binding in nuclear extracts from doxorubicin- or ionizing radiation (IR)-treated human cells, we observed little difference in binding profiles. Significant p53 binding was observed for most polymorphic REs and several displayed binding comparable to the p21 RE. SNP alleles predicted to lower p53 binding indeed reduced binding in 25 of the 32 sequences. Chromatin immunoprecipitation-sequencing in lymphoblastoid cells confirmed p53 binding to seven polymorphic p53 REs in response to doxorubicin. In addition, five polymorphisms were associated with altered gene expression following doxorubicin treatment. Our findings demonstrate an effective strategy to identify and evaluate SNPs that may alter p53-mediated stress responses.
authors.affiliation: Environmental Genomics Group, Laboratory of Molecular Genetics, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA.
authors.forename: Omari J
authors.initials: OJ
authors.lastname: Bandele
authors.forename: Xuting
authors.initials: X
authors.lastname: Wang
authors.forename: Michelle R
authors.initials: MR
authors.lastname: Campbell
authors.forename: Gary S
authors.initials: GS
authors.lastname: Pittman
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Bell
mesh_terms: D000483:Alleles; D001665:Binding Sites; D002478:Cells, Cultured; D047369:Chromatin Immunoprecipitation; D019295:Computational Biology; D004249:DNA Damage; D004317:Doxorubicin / Q000494:pharmacology; D006801:Humans; D020641:Polymorphism, Single Nucleotide; D011485:Protein Binding; D020218:Response Elements; D017422:Sequence Analysis, DNA; D014158:Transcription, Genetic / Q000187:drug effects; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D004317:Doxorubicin
references.citation: Bioinformatics. 2009 Jul 15;25(14):1754-60
references.pmid: 19451168
references.citation: Cell. 1994 Dec 2;79(5):817-27
references.pmid: 8001119
references.citation: J Cancer Res Clin Oncol. 1998;124(2):117-26
references.pmid: 9654195
references.citation: Proc Natl Acad Sci U S A. 2005 May 3;102(18):6431-6
references.pmid: 15843459
references.citation: Cancer Res. 2008 Dec 1;68(23):9671-7
references.pmid: 19047144
references.citation: Biochem Biophys Res Commun. 2002 Mar 29;292(2):492-7
references.pmid: 11906189
references.citation: Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1406-11
references.pmid: 16432214
references.citation: J Biol Chem. 1996 Jun 14;271(24):14412-20
references.pmid: 8662930
references.citation: Environ Health Perspect. 2003 Jun;111(8):1055-64
references.pmid: 12826477
references.citation: Oncogene. 2008 Jul 3;27(29):4013-23
references.pmid: 18278067
references.citation: PLoS Genet. 2008 Jun 27;4(6):e1000104
references.pmid: 18714371
references.citation: Mol Cell. 2003 Oct;12(4):1015-27
references.pmid: 14580351
references.citation: Cell. 2006 Jan 13;124(1):207-19
references.pmid: 16413492
references.citation: Mol Cell Biol. 1992 Jun;12(6):2866-71
references.pmid: 1588974
references.citation: Nat Genet. 2003 Apr;33(4):439-40
references.pmid: 12665861
references.citation: Cancer Res. 2009 Nov 1;69(21):8463-71
references.pmid: 19843844
references.citation: Mol Biol Evol. 2002 Jul;19(7):1114-21
references.pmid: 12082130
references.citation: Hum Mol Genet. 2007 May 15;16(10):1188-200
references.pmid: 17409198
references.citation: J Hum Genet. 2003;48(9):447-450
references.pmid: 12955585
references.citation: Mutat Res. 2004 May 9;560(1):1-10
references.pmid: 15099818
references.citation: Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):1998-2002
references.pmid: 8134338
references.citation: PLoS Genet. 2007 Jul;3(7):e127
references.pmid: 17677004
references.citation: Cancer Res. 2005 Apr 15;65(8):3428-36
references.pmid: 15833878
references.citation: EMBO J. 2000 Sep 15;19(18):4967-75
references.pmid: 10990460
references.citation: FEBS Lett. 1999 Nov 26;462(1-2):85-8
references.pmid: 10580097
references.citation: Mol Cell Biol. 2002 Dec;22(24):8612-25
references.pmid: 12446780
references.citation: Nat Rev Mol Cell Biol. 2008 May;9(5):402-12
references.pmid: 18431400
references.citation: Genes Immun. 2001 Apr;2(2):105-9
references.pmid: 11393654
references.citation: Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):11936-41
references.pmid: 11035798
references.citation: Mol Cell Biol. 2006 Oct;26(19):7030-45
references.pmid: 16980608
references.citation: Cancer Immunol Immunother. 2006 Apr;55(4):355-62
references.pmid: 16187084
references.citation: Nat Genet. 1999 Jun;22(2):145-50
references.pmid: 10369255
references.citation: Mol Endocrinol. 2003 Mar;17(3):356-65
references.pmid: 12554766
references.citation: Cancer Res. 2003 Apr 15;63(8):1756-8
references.pmid: 12702557
references.citation: Mol Cell Biol. 2006 Sep;26(18):6859-69
references.pmid: 16943427
references.citation: Hum Mol Genet. 1994 Sep;3(9):1537-42
references.pmid: 7833908
references.citation: Leuk Res. 2007 Jul;31(7):995-1001
references.pmid: 17257675
references.citation: Cell. 2004 Feb 20;116(4):499-509
references.pmid: 14980218
references.citation: Proteomics. 2006 Jan;6(2):498-504
references.pmid: 16317774
references.citation: Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):84-90
references.pmid: 16002116
references.citation: Nucleic Acids Res. 2003 Jul 15;31(14):e73
references.pmid: 12853650
references.citation: Cancer Res. 2002 Dec 15;62(24):7316-27
references.pmid: 12499275
references.citation: Nucleic Acids Res. 2007;35(9):2986-3001
references.pmid: 17439973
references.citation: Oncogene. 2004 May 20;23(23):4050-9
references.pmid: 15064739
references.citation: PLoS Genet. 2009 May;5(5):e1000462
references.pmid: 19424414
references.citation: J Clin Endocrinol Metab. 2004 Jan;89(1):344-51
references.pmid: 14715870
references.citation: Oncogene. 2007 Apr 2;26(15):2191-201
references.pmid: 17401428
references.citation: Nat Genet. 1992 Apr;1(1):45-9
references.pmid: 1301998
references.citation: Nucleic Acids Res. 2008 Mar;36(5):1589-98
references.pmid: 18234719
references.citation: Nat Methods. 2008 Sep;5(9):829-34
references.pmid: 19160518
references.citation: Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14373-8
references.pmid: 19597154
references.citation: Genes Dev. 2000 Apr 15;14(8):981-93
references.pmid: 10783169
references.citation: Mol Biol Rep. 1997 Mar;24(1-2):57-62
references.pmid: 9228282
references.citation: Genome Res. 2007 Nov;17(11):1586-95
references.pmid: 17908822